Neuralink Investment Thesis

By Akaash TK, Tasha Keeney, CFA

Research Associate, Autonomous Technology & Robotics

Akaash TK joined ARK in July 2024. As an Investment Research Associate, he is responsible for aiding investment decisions by analyzing and evaluating opportunities in the Robotics and Autonomous Technology sector, focusing on innovations that drive significant market impact and value growth.

Director of Research, Autonomous Technology & Robotics / Director of Investment Analysis

As Director of Investment Analysis and Institutional Strategies, Tasha oversees financial modeling across the research teams and manages the strategic opportunities associated with ARK’s institutional efforts. Tasha's research focuses on autonomous technology and additive manufacturing.

Exemplifying the convergence of artificial intelligence, robotics, and multiomics technologies, we believe Neuralink represents one of the most compelling opportunities in the ARK Venture Fund portfolio. The company builds brain-computer interfaces (BCIs) that translate neural signals into digital commands with a speed of iteration, depth of engineering talent, and scale of ambition that no competitor has matched. As of April 30, 2026, Neuralink is the 12th largest holding in the ARK Venture Fund at ~2.12% weighting, a position size that reflects our conviction in the near-term clinical trajectory and long-term economic potential of the platform. 

The clinical evidence is building. Twenty-one patients have received the implant through the PRIME Study as of January 2026, with trials now expanding across the United States, Canada, the United Kingdom, and the United Arab Emirates.¹ The N1 device delivers 1,024 electrodes across 128 ultra-thin polymer threads, a ten-fold increase in channel count over the Utah Array's 96 electrodes, the prior clinical standard for decades.² Higher channel counts translate into richer neural data, enabling more precise decoding of motor intent and, eventually, of sensory input. Neuralink's R1 surgical robot is the only automated system among major BCI programs in human clinical use designed for high-density flexible electrode implantation, combining computer vision and machine learning to place threads with micron level accuracy. The company holds 67 patents globally across 31 patent families as of April 2026,³ creating meaningful barriers to replication. 

Distinguishing Neuralink from its competitors is the integration of hardware, software, and manufacturing under one roof. BCIs require simultaneous excellence in electrode design, real-time neural signal processing, surgical delivery, and iterative clinical development. Few organizations possess the capital, technical breadth, or operational tempo to pursue all four at once. Neuralink has raised more than $1 billion thus far, reaching a ~$9 billion valuation in its latest Series E round.⁴ With 492 employees⁵ and a dedicated 112,000-square-foot production facility, the company is designed to manufacture at scale. 

Neuralink’s multi-product pipeline reinforces the “platform” nature of its technology. Telepathy targets the motor cortex for patients with paralysis. Blindsight addresses the visual cortex for those who have lost sight. VOICE decodes the speech motor cortex to give voice back to those who can no longer speak. CONVOY extends Telepathy’s reach beyond screens, allowing existing implant users to control assistive robotic arms with their thoughts. Each product extends the same core electrode and decoding architecture into a new clinical domain, creating compounding returns on the underlying research and development investment. AI training costs that our research shows have declined ~75% per year since 2020 make real-time neural signal decoding increasingly practical and affordable, a tailwind that benefits Neuralink's software stack directly. 

The competitive landscape includes Synchron, which uses an endovascular approach that avoids craniotomy⁶; Paradromics, which claims data rates exceeding 200 bits per second⁷; and Blackrock Neurotech, which brings more than 20 years of research heritage.⁸ Our analysis also suggests that Neuralink's combination of electrode density, automated surgical delivery, and pace of clinical enrollment positions it to become best in class. That said, Neuralink remains pre-revenue, and Food and Drug Administration (FDA) approval timelines, manufacturing yield, and payer reimbursement pathways are risks to the timing of commercialization. 

Finally, a compelling asymmetry sweetens Neuralink’s market potential. The global neuromodulation market reached $6.37 billion in 2025,⁹ but that figure captures only today's limited device categories. BCIs capable of high-bandwidth bidirectional communication between the brain and external devices represent an entirely new product category whose addressable market should expand significantly as clinical indications, regulatory approvals, and reimbursement frameworks mature. As we discussed in ARK’s Q4 2025 Venture Fund update, Neuralink is a natural fit for ARK’s venture mandate. The company sits at the convergence of multiple technology platforms, and its team has both the engineering talent and the capital to take on a problem whose solution should improve millions of lives. The full ARK Venture Fund portfolio reflects that conviction across a range of similarly positioned companies. 

In our view, Neuralink is not a bet on a single device. It is an investment in an entirely new platform. 

Important information 

We offer our view of Neuralink because it is part of the total ARK Venture Fund portfolio. To see the most updated portfolio and fund holdings, please click here. Holdings subject to change. Not a recommendation to buy, sell, or hold any specific security. 

BEFORE INVESTING YOU SHOULD CAREFULLY CONSIDER THE FUND’S INVESTMENT OBJECTIVES, RISKS, CHARGES AND EXPENSES. THIS AND OTHER INFORMATION IS IN THE PROSPECTUS, A COPY OF WHICH MAY BE OBTAINED HERE. PLEASE READ THE PROSPECTUS CAREFULLY BEFORE YOU INVEST. 

There is no assurance that the Fund will meet its investment objective. The value of your investment in the Fund, as well as the amount of return you receive on your investment in the Fund, may fluctuate significantly. You may lose part or all of your investment in the Fund or your investment may not perform as well as other similar investments. Therefore, you should consider carefully the risks at the bottom of this page before investing in the Fund. 

ARK Investment Management LLC is the investment adviser to the ARK Venture Fund. 

Foreside Fund Services, LLC, distributor.